Following the success of the first edition in 2017 dedicated to the development of therapeutic antibodies to fight infectious diseases, this year's I4ID highlighted the development of host-directed therapies to fight Infectious Diseases.
This second edition of I4ID, organized by MabDesign and BIOASTER was held in Lyon on December 10 & 11 at Matmut Stadium, at the heart of Gerland's "life sciences" ecosystem. For two days more than 150 participants from large groups, SMEs, start-ups, researchers and doctoral students were able to exchange with French and international experts on the latest innovations and scientific advancements.
The two-day program highlighted the work developed by industrials companies, such as Atox Bio (Israel), Innate Pharma (France), bioMérieux (France), Enyo Pharma (France) and RemAb Therapeutics (Spain), as well as prestigious research institutes such as the Max Planck Institute for Infection Biology (Germany), Institut Pasteur (France), Foundation Champalimaud (Portugal), University College of London (United Kingdom), CIRI (France), and also clinicians such as University of Washington School of Medicine (United States), Hospices Civils de Lyon (France), and Bellvitge University Hospital (Spain), among others.
The Pitch Session showcased the latest innovations and expertise in the field from companies, research institutes and hospitals. More than 150 B2B meetings were held, sharing know-how, finding new customers and establishing partnerships. The success of this 2nd edition also takes into account the support of several partners, such as SANOFI, bioMérieux, GSK, La Métropole ONLY LYON, FINOVI, Transgene, Inserm as well as all our institutional and media partners.
The I4ID2017 Congress, which took place on Monday 11th & Tuesday 12th December 2017 at Lyon’s Congress Center, gathered together more than 175 attendees, 80 organizations, academics, businesses and 33 internationally renowned speakers.
Co-organised by the Technological Research Institute BIOASTER and the MabDesign association, this event was the first of its kind in France. The diversity of the program of I4ID brought together, over two days, industrials, academics, clinicians, service providers, technology developers and international decision makers to discuss and exchange on immunotherapy as a new therapeutic way to fight emerging or re-emerging infectious diseases.